Jefferies and Leerink Partners are acting as the joint book-running managers for the offering and Wedbush PacGrow is acting as co-manager.
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: TVTX) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, shares of ...
The deal priced below last closing price of $17.66. Jefferies and Leerink are acting as joint book running managers for the offering.
Travere Therapeutics (NASDAQ:TVTX – Get Free Report) had its price objective lifted by investment analysts at Barclays from ...
Travere Therapeutics Inc (NASDAQ:TVTX) is set to release its Q3 2024 earnings on1, 2024. The consensus estimate for Q3 2024 ...
Travere Therapeutics (NASDAQ:TVTX), a biopharmaceutical company focused on developing treatments for rare diseases, has been making significant strides in the market. The company's recent ...
Live webcasts of the presentations will be accessible on the Investor page of Travere's website at ir.travere.com/events-presentations, and replays will be available for up to 30 days following each ...
Q3 2024 Earnings Call Transcript October 31, 2024 Travere Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...
SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in ...
SAN DIEGO (AP) — SAN DIEGO (AP) — Travere Therapeutics, Inc. (TVTX) on Thursday reported a loss of $54.8 million in its third quarter. On a per-share basis, the San Diego-based company said it had a ...
Travere Therapeutics (NASDAQ:TVTX), a biopharmaceutical company focused on developing treatments for rare diseases, has been making significant strides in the market. The company's recent achievements ...